These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 14552799)

  • 21. Discovery and evaluation of N-(triazin-1,3,5-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
    Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Hutchinson B; Parton TA; Robinson MK; Shock A; Warrellow GJ; Zomaya A
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1591-4. PubMed ID: 12039569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
    Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amidines as amide bond replacements in VLA-4 antagonists.
    Kamenecka TM; Park YJ; Lin LS; de Laszlo S; McCauley ED; Van Riper G; Egger L; Kidambi U; Mumford RA; Tong S; Tang W; Colletti A; Teffera Y; Stearns R; MacCoss M; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2004 May; 14(9):2323-6. PubMed ID: 15081033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow.
    White J; Krishnamoorthy S; Gupta D; Lancelot M; Moore N; Sarnaik S; Hobbs WE; Light DR; Hines P
    Br J Haematol; 2016 Sep; 174(6):970-82. PubMed ID: 27291690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of a 2-azabicyclo[2.2.2]octane-based alpha4beta1 integrin antagonist as an inhaled anti-asthmatic agent.
    Lawson EC; Santulli RJ; Dyatkin AB; Ballentine SA; Abraham WM; Rudman S; Page CP; de Garavilla L; Damiano BP; Kinney WA; Maryanoff BE
    Bioorg Med Chem; 2006 Jun; 14(12):4208-16. PubMed ID: 16495061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-(3-phenylsulfonyl-3-piperidinoyl)-phenylalanine derivatives as potent, selective VLA-4 antagonists.
    Gutteridge CE; de Laszlo SE; Kamenecka TM; McCauley E; van Riper G; Mumford RA; Kidambi U; Egger LA; Tong S; Hagmann WK
    Bioorg Med Chem Lett; 2003 Mar; 13(5):885-90. PubMed ID: 12617914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
    Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
    Setoguchi M; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Muro F; Iigo Y; Takayama G; Yokoyama M; Taira T; Aonuma M; Takashi T; Nakayama A; Machinaga N
    Bioorg Med Chem; 2013 Jan; 21(1):42-61. PubMed ID: 23218775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rational design of potent and selective VLA-4 inhibitors and their utility in the treatment of asthma.
    Singh J; Adams S; Carter MB; Cuervo H; Lee WC; Lobb RR; Pepinsky RB; Petter R; Scott D
    Curr Top Med Chem; 2004; 4(14):1497-507. PubMed ID: 15544540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2,3-Diphenylpropionic acids as potent VLA-4 antagonists.
    Hoshina Y; Ikegami S; Okuyama A; Fukui H; Inoguchi K; Maruyama T; Fujimoto K; Matsumura Y; Aoyama A; Harada T; Tanaka H; Nakamura T
    Bioorg Med Chem Lett; 2005 Jan; 15(1):217-20. PubMed ID: 15582442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The discovery of VLA-4 antagonists.
    Tilley JW; Chen L; Sidduri A; Fotouhi N
    Curr Top Med Chem; 2004; 4(14):1509-23. PubMed ID: 15544541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation.
    Koo GC; Shah K; Ding GJ; Xiao J; Wnek R; Doherty G; Tong XC; Pepinsky RB; Lin KC; Hagmann WK; Kawka D; Singer II
    Am J Respir Crit Care Med; 2003 May; 167(10):1400-9. PubMed ID: 12569079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focused library approach for identification of new N-acylphenylalanines as VCAM/VLA-4 antagonists.
    Chen L; Trilles R; Miklowski D; Huang TN; Fry D; Campbell R; Rowan K; Schwinge V; Tilley JW
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1679-82. PubMed ID: 12039589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma.
    Ravensberg AJ; Luijk B; Westers P; Hiemstra PS; Sterk PJ; Lammers JW; Rabe KF
    Allergy; 2006 Sep; 61(9):1097-103. PubMed ID: 16918513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient synthesis of 3-aminocyclobut-2-en-1-ones: squaramide surrogates as potent VLA-4 antagonists.
    Brand S; de Candole BC; Brown JA
    Org Lett; 2003 Jun; 5(13):2343-6. PubMed ID: 12816444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The inhibition of the integrin VLA-4 in MV3 melanoma cell binding by non-anticoagulant heparin derivatives.
    Schlesinger M; Schmitz P; Zeisig R; Naggi A; Torri G; Casu B; Bendas G
    Thromb Res; 2012 May; 129(5):603-10. PubMed ID: 22099706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imidazopyridines as VLA-4 integrin antagonists.
    Phillips DJ; Davenport RJ; Demaude TA; Galleway FP; Jones MW; Knerr L; Perry BG; Ratcliffe AJ
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4146-9. PubMed ID: 18539454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of unique VLA-4 antagonists from a combinatorial library.
    de Laszlo SE; Li B; McCauley E; Van Riper G; Hagmann WK
    Bioorg Med Chem Lett; 2002 Feb; 12(4):685-8. PubMed ID: 11844701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.
    Pepinsky RB; Lee WC; Cornebise M; Gill A; Wortham K; Chen LL; Leone DR; Giza K; Dolinski BM; Perper S; Nickerson-Nutter C; Lepage D; Chakraborty A; Whalley ET; Petter RC; Adams SP; Lobb RR; Scott DM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):742-50. PubMed ID: 15485895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dehydrophenylalanine derivatives as VLA-4 integrin antagonists.
    Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Parton TA; Robinson MK; Shock A; Taylor RJ; Warrellow GJ
    Bioorg Med Chem Lett; 2003 Mar; 13(5):805-8. PubMed ID: 12617895
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.